Latest Market News

Syntara Limited has initiated dosing in its Phase 1a/b trial for SNT-9465, a topical drug targeting hypertrophic scars, aiming to offer a non-invasive alternative to current treatments. Results expected in early 2026 could pave the way for global development and FDA approval.

Alpha HPA Limited has kicked off major civil works for its HPA First Project Stage 2 while securing strong sales momentum in the semiconductor sector, supported by expanded Letters of Intent covering over 60% of Stage 2 capacity.

First Lithium Limited is on the cusp of securing critical mining license renewals in Mali and anticipates releasing its maiden Mineral Resource Estimate this quarter, while managing funding and exploration cost pressures.

Kalamazoo Resources retains 100% ownership of its 1.44 million ounce Ashburton Gold Project and fast-tracks a scoping study amid soaring Australian gold prices. The company aims to unlock significant value from the Mt Olympus Deposit with a targeted study completion in Q4 2025.

Clime Investment Management has reported a solid operating profit for the June quarter, declared a fully franked dividend, and announced strategic expansions in staff and product offerings.

DUG Technology's US subsidiary is heading to trial over a disputed $2.4 million supplier invoice, with a counterclaim of $3.1 million adding complexity to the Texas court battle.

Clever Culture Systems advances its pharmaceutical market penetration with AstraZeneca’s full deployment and Novo Nordisk’s first order, while launching a new contact plate analysis module that doubles its APAS Independence system’s capabilities.

Acrow Limited confirms FY25 financial guidance with solid sales and EBITDA growth, while securing a significant seven-year contract extension with Origin Energy that bolsters its Industrial Access division outlook for FY26.

Bastion Mining has taken control of over 90% of Xanadu Mines shares through a takeover bid, moving swiftly to compulsory acquisition and setting the stage for the Kharmagtai project’s next phase.

Paradigm Biopharmaceuticals has advanced its global Phase 3 trial for knee osteoarthritis pain with active patient recruitment in Australia and the US, backed by a $41.2 million convertible note facility. The company also expanded its osteoarthritis portfolio through the acquisition of Proteobioactives and the Pentacoxib™ oral therapy.

Global Uranium and Enrichment Limited’s investee Ubaryon has sealed a binding agreement with uranium giant Urenco, unlocking a A$5 million investment and technical collaboration to accelerate a novel uranium enrichment technology.

OpenLearning Limited reported a robust Q2 FY25 with 22% year-on-year SaaS ARR growth to $2.65 million, driven by significant multi-year contract wins and expanding global customer base. The company’s AI-powered LMS strategy is delivering larger deals and improved cash flow metrics.